↓ Skip to main content

Decrease in Blood Pressure and Regression of Cardiovascular Complications by Angiotensin II Vaccine in Mice

Overview of attention for article published in PLOS ONE, March 2013
Altmetric Badge

About this Attention Score

  • Good Attention Score compared to outputs of the same age (68th percentile)
  • Above-average Attention Score compared to outputs of the same age and source (63rd percentile)

Mentioned by

twitter
4 X users

Citations

dimensions_citation
45 Dimensions

Readers on

mendeley
53 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Decrease in Blood Pressure and Regression of Cardiovascular Complications by Angiotensin II Vaccine in Mice
Published in
PLOS ONE, March 2013
DOI 10.1371/journal.pone.0060493
Pubmed ID
Authors

Futoshi Nakagami, Hiroshi Koriyama, Hironori Nakagami, Mariana Kiomy Osako, Munehisa Shimamura, Mariko Kyutoku, Takashi Miyake, Tomohiro Katsuya, Hiromi Rakugi, Ryuichi Morishita

Abstract

Vaccines have been recently developed to treat various diseases such as cancer, rheumatoid arthritis and Alzheimer's disease in addition to infectious diseases. However, before use in the clinical setting, vaccines targeting self-antigens must be demonstrated to be effective and safe, evoking an adequate humoral immune response from B cells while avoiding T cell activation in response to self. Although the vaccine targeting angiotensin II (Ang II) is efficient in rodents and humans, little is known regarding the immunological activation and safety of the vaccine. In this study, we evaluated the efficiency and safety of an Ang II peptide vaccine in mice. Immunization with Ang II conjugated to keyhole limpet hemocyanin (KLH) successfully induced the production of anti-Ang II antibody, which blocked Ang II signaling in human aortic smooth muscle cells. However, Ang II itself did not activate T cells, as assessed by the proliferation and lymphokine production of T cells in immunized mice, whereas KLH activated T cells. In an Ang II-infused model, the non-immunized mice showed high blood pressure (BP), whereas the immunized mice (Ang II-KLH) showed a significant decrease in systolic BP, accompanied by significant reductions in cardiac hypertrophy and fibrosis. Importantly, anti-Ang II antibody titer was not elevated even after the administration of large amounts of Ang II, indicating that Ang II itself boosted antibody production, most likely due to less activation of T cells. In addition, no accumulation of inflammatory cells was observed in immunized mice, because endogenous Ang II would not activate T cells after immunization with Ang II-KLH. Taken together, these data indicate that vaccines targeting Ang II might be effective to decrease high BP and prevent cardiovascular complications without severe side effects.

X Demographics

X Demographics

The data shown below were collected from the profiles of 4 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 53 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Kenya 1 2%
Unknown 52 98%

Demographic breakdown

Readers by professional status Count As %
Researcher 8 15%
Student > Bachelor 7 13%
Student > Master 6 11%
Student > Doctoral Student 5 9%
Professor > Associate Professor 5 9%
Other 15 28%
Unknown 7 13%
Readers by discipline Count As %
Medicine and Dentistry 27 51%
Agricultural and Biological Sciences 6 11%
Biochemistry, Genetics and Molecular Biology 3 6%
Unspecified 2 4%
Chemistry 2 4%
Other 6 11%
Unknown 7 13%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 4. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 28 March 2013.
All research outputs
#7,115,857
of 22,703,044 outputs
Outputs from PLOS ONE
#84,311
of 193,827 outputs
Outputs of similar age
#62,153
of 197,839 outputs
Outputs of similar age from PLOS ONE
#1,927
of 5,337 outputs
Altmetric has tracked 22,703,044 research outputs across all sources so far. This one has received more attention than most of these and is in the 68th percentile.
So far Altmetric has tracked 193,827 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 15.0. This one has gotten more attention than average, scoring higher than 56% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 197,839 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 68% of its contemporaries.
We're also able to compare this research output to 5,337 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 63% of its contemporaries.